Elevation Oncology Stock Price To Sales
| ELEVDelisted Stock | USD 0.37 0.00 0.00% |
Fundamental analysis of Elevation Oncology allows traders to better anticipate movements in Elevation Oncology's stock price by examining its financial health and performance throughout various phases of its business cycle.
Elevation |
Elevation Oncology Company Price To Sales Analysis
Elevation Oncology's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Elevation Oncology has a Price To Sales of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to sales for all United States stocks is 100.0% higher than that of the company.
Elevation Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Elevation Oncology's direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Elevation Oncology could also be used in its relative valuation, which is a method of valuing Elevation Oncology by comparing valuation metrics of similar companies.Elevation Oncology is currently under evaluation in price to sales category among its peers.
Elevation Fundamentals
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.3 | ||||
| Current Valuation | (27.78 M) | ||||
| Shares Outstanding | 59.25 M | ||||
| Shares Owned By Insiders | 0.35 % | ||||
| Shares Owned By Institutions | 59.72 % | ||||
| Number Of Shares Shorted | 2.08 M | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 0.46 X | ||||
| EBITDA | (44.7 M) | ||||
| Net Income | (44.48 M) | ||||
| Cash And Equivalents | 122.54 M | ||||
| Cash Per Share | 5.26 X | ||||
| Total Debt | 31.13 M | ||||
| Current Ratio | 6.48 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (36.36 M) | ||||
| Short Ratio | 0.91 X | ||||
| Earnings Per Share | (0.81) X | ||||
| Target Price | 0.4 | ||||
| Number Of Employees | 34 | ||||
| Beta | 1.5 | ||||
| Market Capitalization | 21.63 M | ||||
| Total Asset | 95.63 M | ||||
| Retained Earnings | (240.46 M) | ||||
| Working Capital | 90.26 M | ||||
| Net Asset | 95.63 M |
About Elevation Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elevation Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elevation Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elevation Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Elevation Stock
If you are still planning to invest in Elevation Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Elevation Oncology's history and understand the potential risks before investing.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |